Zydus Brings the First Keytruda Biosimilar Showdown to North America
Zydus Lifesciences has taken a major step into the global oncology biosimilar battlefield after announcing it will commercialize Formycon AG’s biosimilar version of Keytruda in the United States and Canada, marking one of the most strategically important biosimilar launches of the decade. Keytruda, Merck’s blockbuster anti-PD-1 antibody, is the world’s highest-selling cancer drug, and its biosimilar transition is expected to reshape immuno-oncology pricing worldwide. Under the agreement, Zydus will handle commercialization while Formycon retains development leadership, creating a transatlantic biosimilar alliance aimed directly at Merck’s stronghold. Analysts expect the move to ignite price competition in checkpoint inhibitors for the first time in North America, potentially unlocking access for thousands of patients while placing new margin pressure on originators.
You May Interested In
2026-09-27
Trade Alert
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Related News
-
Procter & Gamble Posts Higher Profits on Strong Personal Care Sales and Recovery in China
-
China National Salt Industry Corporation Advances 10,000 t/y Sodium Metal Expansion Project, Industry Leader Invests Nearly RMB 100 Million
-
Henkel's Acquisition of Stahl Enters Regulatory Countdown: Will the €2.1 Billion Deal Go Through?
-
BASF Ludwigshafen Workforce Falls Below 30,000, Lowest Level in 72 Years
-
DyStar Becomes a Wholly-Owned Subsidiary of Zhejiang Longsheng Group, Ending Longstanding Shareholder Disputes with a $5 Billion Deal
-
Wanhua Chemical's 240,000-ton/year Iron Phosphate Project Approved
-
Pharmaceutical State-Owned Enterprise Acquires Leading Pesticide Company for RMB 5.656 Billion, Betting on Synthetic Biology Industrialization
-
BASF Brings Biomass-Balance Polyols to North America
-
Henkel to Acquire Olaplex in $1.4 Billion Deal
-
Due to Supply Chain Disruptions, A Major MDI/TDI Facility in the Middle East has Suddenly Shut Down!
Recommend Reading
-
![$14.5 Billion Solstice–Element Solutions Merger Abruptly Terminated Less Than Two Months After Announcement]()
$14.5 Billion Solstice–Element Solutions Merger Abruptly Terminated Less Than Two Months After Announcement
-
![Lotte Merges with HD Hyundai: Can Korea’s Petrochemical First Case Trigger True Restructuring?]()
Lotte Merges with HD Hyundai: Can Korea’s Petrochemical First Case Trigger True Restructuring?
-
![Pregabalin vs Gabapentin: Differences, Uses, and Side Effects]()
Pregabalin vs Gabapentin: Differences, Uses, and Side Effects
-
![Hormuz Crisis Exposes India’s Agrochemical “First Mile”]()
Hormuz Crisis Exposes India’s Agrochemical “First Mile”
-
![Hormuz Crisis Exposes India’s Agrochemical “First Mile”]()
Hormuz Crisis Exposes India’s Agrochemical “First Mile”
-
![Phosphoric Acid Market Trends in November Show a Strong Uptrend]()
Phosphoric Acid Market Trends in November Show a Strong Uptrend
-
![Business Society’s Market Outlook for Epoxy Resins on August 28, 2026: Stable Operation]()
Business Society’s Market Outlook for Epoxy Resins on August 28, 2026: Stable Operation
-
![Crude Oil Surge Leads to Significant Increase in This Round of Retail Fuel Prices in China]()
Crude Oil Surge Leads to Significant Increase in This Round of Retail Fuel Prices in China
-
![Weakness in Polyethylene Continues in November]()
Weakness in Polyethylene Continues in November
-
![Business Society’s BDO Market Outlook on August 27, 2026: Clearly Upward]()
Business Society’s BDO Market Outlook on August 27, 2026: Clearly Upward
